GAC0001E5 is a novel LXR inverse agonist, functioning as LXR a "degrader", significantly reducing LXR protein levels in PDAC cell lines.
Uses
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies[1].
References
[1] Karaboga H, et al. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity. ACS Chem Biol. 2020 Nov 20;15(11):2916-2928. DOI:10.1021/acschembio.0c00546
